NCT00839059终止1 期
Open-Label, Multi-Center Phase I Dose-Escalation Study With Lenalidomide In Patients With Acute Myeloid Leukemia
University of Ulm6 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2009年1月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 发起方
- 入组人数
- 14
- 试验地点
- 6
- 主要终点
- Dose-Limiting Toxicities (DLTs), Maximum tolerated dose (MTD)
研究概览
简要总结
This is a Phase I, open-label, multi-center, dose-escalation study of lenalidomide in adult patients with newly diagnosed, relapsed or refractory acute myeloid leukemia. All patients will receive lenalidomide per oral daily (starting dose is 25 mg/d). Cohorts of 3 patients (to be expanded up to 6 if 1 dose-limiting toxicity (DLT) is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide-related toxicity or lenalidomide related serious adverse reactions encountered in the first cycle. For the purpose of this study, patients' enrollment will continue until the maximum tolerated dose (MTD) will be determined and characterized.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Disease state:
- •Age > 70 years newly diagnosed AML (including de novo, s-AML, t-AML)considered ineligible for intensive treatment. Ineligibility for intensive treatment has to be documented within the case report forms (Medical/Oncologic History).
- •Age > 60 years relapsed/refractory AML in medically fit patients and newly diagnosed AML (including de novo, s- AML,t-AML) in medically unfit patients
- •Age 18-60 years: second or higher relapse of AML, not eligible for intensive therapy
- •WBC <20x109/l, pretreatment with hydroxyurea is allowed to lower WBC
- •Prior chemo-immunotherapy and other study-medications must have been completed 2 weeks before study treatment start. Treatment with hydroxyureas should be discontinued 1 day before initiating dosing with lenalidomide
- •Willingness and ability to comply with scheduled visits,treatment plan, laboratory tests and other study procedures
- •Females of childbearing potential (FCBP)† must agree to use two reliable forms of contraception simultaneously or to practice complete abstinence from - FCBP must have two negative pregnancy tests (sensitivity of at least 50 mIU/mL) prior to starting study drug.
- •Male subjects must agree to use a latex condom during sexual contact with females of childbearing potential while participating in the study and for at least 28 days following discontinuation from the study even if he has undergone a successful vasectomy.
排除标准
- •Acute promyelocytic leukemia [t(15;17)]
- •bleeding disorder independent of the AML
- •uncontrolled infection
- •insufficiency of the kidneys (creatinin >1.5x upper normal serum level), of the liver (bilirubin, AST or AP > 2x upper normal serum level)
- •severe obstructive or restrictive ventilation disorder
- •heart failure NYHA III/IV
- •severe neurological or psychiatric disorder interfering with ability of giving an informed consent
- •no consent for registration, storage and processing of the individual disease-characteristics and course
- •peripheral neuropathy
- •Performance status WHO > 2
- •Presence of any medical/psychiatric condition or laboratory abnormalities which may limit full compliance with the study, increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for entry into this study
- •Pregnancy or breast-feeding
- •Known positive for HIV or infectious hepatitis, type A, B or C
- •Known hypersensitivity to thalidomide
- •Any prior use of lenalidomide
- •Drug or alcohol abuse within the last 6 months
- •Participating in other studies within the last 2 weeks
研究组 & 干预措施
Lenalidomide
Experimental
干预措施: lenalidomide (Drug)
结局指标
主要结局
Dose-Limiting Toxicities (DLTs), Maximum tolerated dose (MTD)
时间窗: 1-56 days
次要结局
- Measurement of the pharmacokinetic profile of lenalidomide(1st and 8th day)
- Objective tumor response, as defined using the revised recommendations of the International Working Group for diagnosis, standardization of response criteria in Acute Myeloid Leukemia for AML(1 year)
研究者
研究点 (6)
Loading locations...
相似试验
已完成
1 期
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid TumorsAdvanced Solid TumorsUndifferentiated Pleomorphic SarcomaSquamous Cell Carcinoma of the Head and NeckCarcinoma of the BreastNCT02565758AbbVie85
撤回
1 期
Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.Non-small Cell Lung Cancer (NSCLC)EndometrialSolid TumorsOvarian CancerLiposarcomaBreast CancerNCT05905341Pfizer
已完成
1 期
First-In-Human Study in Subjects With Advanced or Metastatic Solid Malignant TumorsAdvanced Solid TumorsMetastatic Solid TumorsNCT05494918Alphamab (Australia) Co Pty Ltd.62
终止
1 期
A Study of AMG 340 in Subjects With Metastatic Castrate-Resistant Prostate CarcinomaMetastatic Castration-resistant Prostate CancerNCT04740034Amgen42
进行中（未招募）
1 期
A Study of TNB-383B in Participants With Relapsed or Refractory Multiple MyelomaMultiple MyelomaNCT03933735AbbVie220